Market closed
PTC Therapeutics/$PTCT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About PTC Therapeutics
PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.
Ticker
$PTCT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
939
Website
PTC Therapeutics Metrics
BasicAdvanced
$4.5B
-
-$4.73
0.66
-
Price and volume
Market cap
$4.5B
Beta
0.66
52-week high
$58.38
52-week low
$24.00
Average daily volume
784K
Financial strength
Current ratio
2.35
Quick ratio
2.258
Long term debt to equity
-200.341
Total debt to equity
-225.038
Interest coverage (TTM)
-0.86%
Management effectiveness
Return on assets (TTM)
-5.09%
Return on equity (TTM)
37.91%
Valuation
Price to revenue (TTM)
5.443
Price to book
-4.04
Price to tangible book (TTM)
-3.42
Price to free cash flow (TTM)
-24.134
Growth
Revenue change (TTM)
-13.97%
Earnings per share change (TTM)
-43.54%
3-year revenue growth (CAGR)
14.42%
3-year earnings per share growth (CAGR)
-14.01%
What the Analysts think about PTC Therapeutics
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for PTC Therapeutics stock.
PTC Therapeutics Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
PTC Therapeutics Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
PTC Therapeutics News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for PTC Therapeutics stock?
PTC Therapeutics (PTCT) has a market cap of $4.5B as of March 23, 2025.
What is the P/E ratio for PTC Therapeutics stock?
The price to earnings (P/E) ratio for PTC Therapeutics (PTCT) stock is 0 as of March 23, 2025.
Does PTC Therapeutics stock pay dividends?
No, PTC Therapeutics (PTCT) stock does not pay dividends to its shareholders as of March 23, 2025.
When is the next PTC Therapeutics dividend payment date?
PTC Therapeutics (PTCT) stock does not pay dividends to its shareholders.
What is the beta indicator for PTC Therapeutics?
PTC Therapeutics (PTCT) has a beta rating of 0.66. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.